Biological Basis for Understanding Psychopharmacology

Neuroimaging in Biological Psychiatry

Advanced Imaging Techniques

  • Positron-Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT):

    • Localize specific brain regions associated with perceptual, cognitive, emotional, and behavioral functions.

    • Provide objective evidence of altered metabolic activity and glucose utilization in unmedicated individuals diagnosed with major depressive disorder, schizophrenia, or obsessive-compulsive disorder (OCD).


PET Scan of Obsessive-Compulsive Disorder showing high orbital glucose metabolism
  • Functional Magnetic Resonance Imaging (fMRI):

    • Measures functional connectivity and communication efficiency between distinct anatomical regions of the brain.

    • Demonstrates higher-order cognitive processing in real time.

    • Holds predictive clinical potential for identifying patient-specific treatment responses to psychotropic medications.

Biological Basis of Psychiatric Illness and Psychotropic Action

Pathophysiology and Biological Etiology

  • Anatomical Locus: All conscious and unconscious mental activity originates within functional neural networks in the brain.

  • Multifactorial Etiology: Psychiatric illnesses develop through complex interactions among diverse factors:

    • Genetic susceptibility

    • Neurodevelopmental abnormalities

    • Pharmacological exposures

    • Infectious agents

    • Psychosocial and environmental experiences

  • Biological Mechanism: Psychiatric conditions manifest as alterations in neurotransmitter synthesis, release, reuptake, or receptor sensitivity. These biological alterations serve as primary targets for psychotropic interventions.

Principles of Nursing Practice in Psychopharmacology

  • Core Goals of Psychiatric Mental Health Nursing:

    • Develop a comprehensive understanding of the neurobiological mechanisms underlying normal and abnormal brain functions.

    • Integrate neurobiological evidence into clinical assessment, monitoring, and administration of psychotropic drug regimens.

Neuroanatomy and Brain Functions

Fundamental Functions of the Brain

  • Maintenance of bodily homeostasis.

  • Regulation of the autonomic nervous system (ANS) and endocrine/hormonal pathways.

  • Control of basic biological drives (hunger, thirst, sex) and complex behaviors.

  • Regulation of the sleep-wake cycle and circadian rhythms.

  • Processing of conscious mental activity, executive functioning, and decision-making.

  • Storage and retrieval of memory.

  • Mediation of social behaviors and interpersonal interactions.

Brain Structures and Functional Localization


Anatomical Diagram of Brain Lobes, Brainstem, and Cerebellum Functions
  • Frontal Lobe:

    • Primary seat of executive function and thought processes.

    • Responsible for goal formulation and selection, initiation, planning, and termination of actions.

    • Mediates decision-making, insight, motivation, and social judgment.

    • Location of origin for voluntary motor commands.

  • Parietal Lobe:

    • Somatosensory processing and motor integration.

    • Receives and interprets sensory inputs.

    • Controls concept formation, abstract thinking, proprioception, and body awareness.

    • Mediates reading comprehension, mathematical calculations, and right-left spatial orientation.

  • Temporal Lobe:

    • Auditory processing center.

    • Responsible for language comprehension and sound memory storage.

    • Direct connectivity with the limbic system ("the emotional brain"), allowing expression of primary emotions including fear, aggression, and sexual behavior.

  • Occipital Lobe:

    • Primary visual processing center.

    • Interprets visual imagery, visual association, and visual memory storage.

    • Integrates visual input into language formation pathways.

  • Cerebellum:

    • Coordinates skeletal muscle contractions and fine motor control.

    • Maintains postural balance and equilibrium.

  • Brainstem Structures:

    • Midbrain: Mediates pupillary reflexes and extraocular movements.

    • Pons: Functions as a major processing station within auditory pathways.

    • Medulla Oblongata: Contains autonomic reflex centers controlling balance, heart rate, respiratory depth and rate, coughing, swallowing, sneezing, blood pressure regulation, and vomiting.

    • Pituitary Gland (Anterior and Posterior): Master endocrine regulator controlling peripheral hormone release under hypothalamic control.

Cellular Mechanisms of Neurotransmission

Electrical and Chemical Signal Conduction

  • Neurotransmission Process:

    • Electrical impulse propagation (conduction) travels down the neuronal axon via rapid membrane depolarization and repolarization, mediated by influx of sodium (Na+\text{Na}^+) ions and efflux of potassium (K+\text{K}^+) ions.

    • Arrival of the action potential at the presynaptic terminal triggers vesicular release of chemical neurotransmitters across the synaptic cleft.

    • Neurotransmitters bind to specific postsynaptic receptors, inducing either excitatory or inhibitory responses in the postsynaptic cell.


Mechanisms of Neurotransmitter Deficiencies and Excesses at the Synapse
  • Synaptic Transmission Abnormalities:

    • Insufficient Transmission: Caused by deficient presynaptic neurotransmitter synthesis/release or a reduction in postsynaptic receptor density.

    • Excessive Transmission: Caused by abnormally elevated presynaptic release or heightened postsynaptic receptor sensitivity (e.g., elevated dopamine signaling in schizophrenia).

Neurotransmitter Inactivation Pathways

  • Enzymatic Degradation: Immediate chemical inactivation of neurotransmitters by specific enzymes located within the synaptic cleft or postsynaptic membrane following receptor detachment.

  • Presynaptic Reuptake: Active transport mechanism where intact neurotransmitters separate from receptors and are transported back into the presynaptic neuron for repackaging into vesicles or intracellular degradation.

Receptor Pharmacodynamics

  • Receptors: Cell-surface or intracellular protein structures that bind specific chemical ligands to alter cellular physiology.

  • Receptor Agonist: An extrinsic drug molecule that binds to a receptor and mimics the action of endogenous ligands, producing a full physiological response.

  • Receptor Antagonist: An extrinsic drug molecule that binds to a receptor site without activating it, competitively or non-competitively blocking endogenous ligands from binding.

Major Neurotransmitter Systems

Monoamines

  • Dopamine (DA):

    • Decrease: Associated with depression and Parkinson's disease.

    • Increase: Associated with schizophrenia, psychosis, and mania.

  • Norepinephrine (NE):

    • Decrease: Associated with depression.

    • Increase: Associated with anxiety disorders, mania, and schizophrenia.

  • Serotonin (5-HT5\text{-HT}):

    • Decrease: Associated with major depressive disorder.

    • Increase: Associated with anxiety states and serotonin toxicity.

  • Histamine (H1\text{H}_1):

    • Decrease: Results in sedation, drowsiness, and weight gain.

Amino Acids

  • Gamma-Aminobutyric Acid (GABA):

    • Main inhibitory neurotransmitter in the central nervous system.

    • Decrease: Associated with anxiety disorders, mania, and schizophrenia.

    • Increase: Reduces anxiety, induces sedation, and produces anticonvulsant effects.

  • Glutamate:

    • Main excitatory neurotransmitter in the central nervous system.

    • NMDA Receptor Hypofunction/Decrease: Impairs learning and memory.

    • NMDA Receptor Hyperfunction/Increase: Induces excitotoxicity and neurodegeneration (seen in Alzheimer's disease).

    • AMPA Receptor Activation: Enhances cognitive performance and memory formation.

Cholinergics

  • Acetylcholine (ACh):

    • Plays a crucial role in memory, learning, and motor control.

    • Decrease: Characteristic of Alzheimer's disease, Huntington's chorea, and Parkinson's disease.

    • Increase: Associated with depressive symptoms.

Neuropeptides / Neuromodulators

  • Substance P: Regulates mood, stress responses, anxiety, and pain transmission pathways.

  • Somatostatin (SRIF):

    • Decrease: Observed in Alzheimer's disease and in the cerebrospinal fluid (CSF) of depressed individuals.

    • Increase: Observed in Huntington's chorea.

  • Neurotensin: Decreased CSF concentrations noted in individuals with schizophrenia.

Pharmacokinetic and Pharmacodynamic Principles

Drug Interaction Categories

  • Pharmacokinetic Interactions:

    • Occur when one drug alters the absorption, distribution, metabolism (e.g., Cytochrome P450 inhibition/induction), or elimination of another agent.

    • Directly alters plasma drug concentrations.

  • Pharmacodynamic Interactions:

    • Occur when drugs exert actions on identical or interconnected receptor systems.

    • Result in additive, synergistic, or antagonist physiological effects.

Polypharmacy and Clinical Complexity

  • Managing drug interactions becomes complex in patients with multiple medical comorbidities.

  • Older adults face heightened risk due to age-related decline in hepatic clearance, renal filtration, and increased likelihood of polypharmacy.

Antidepressant Medications

Monoamine Oxidase Inhibitors (MAOIs)

  • Mechanism of Action: Inhibit the monoamine oxidase (MAO) enzyme responsible for catabolizing monoamine neurotransmitters (dopamine, norepinephrine, epinephrine, serotonin), thereby increasing synaptic monoamine availability.

  • Drug Classifications:

    • Oral Agents: Phenelzine (Nardil), Tranylcypromine (Parnate), Isocarboxazid (Marplan).

    • Transdermal System: Selegiline transdermal system (EMSAM) — delivers MAOIs continuously through the skin.


MAO Inhibitors Interactions, Dietary Restrictions, and Adverse Effects
  • Hypertensive Crisis:

    • Occurs when patients taking MAOIs ingest tyramine-containing substances or sympathomimetic drugs.

    • Tyramine acts as an indirect sympathomimetic agent, triggering massive norepinephrine release.

    • Restricted Foods: Aged cheeses, milk products, Chianti wine, draft beer, preserved/cured meats (salami), avocados, organ meats, overripe fruit.

    • Contraindicated Medications ("No Popular Meds Ever"): Tricyclic antidepressants, SSRIs, indirect-acting sympathomimetics, antihypertensives, OTC cold/cough remedies, asthma inhalers, decongestants.

    • Dietary Restrictions Timeline: Tyramine restrictions must be strictly maintained during therapy and for at least 2 weeks2\,\text{weeks} following drug discontinuation.

    • Clinical Presentation: Severe occipital headache, profuse sweating, palpitations, nausea, vomiting, severe hypertension, tachycardia.

    • Emergency Nursing Interventions:

    • Immediately discontinue the MAOI.

    • Assess and monitor vital signs.

    • Administer short-acting antihypertensive agents (e.g., phentolamine or nitroprusside).

    • Apply cooling blankets or tepid baths for hyperthermia.

    • Manage symptoms and maintain airway.

Selective Serotonin Reuptake Inhibitors (SSRIs)

  • Representative Agents: Fluoxetine (Prozac), Sertraline (Zoloft), Paroxetine (Paxil), Citalopram (Celexa), Escitalopram (Lexapro).

  • Mechanism of Action: Selectively block the presynaptic reuptake transporter for serotonin (5-HT5\text{-HT}), increasing synaptic concentration.

  • Clinical Indications: Major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder.

  • Onset of Action: Therapeutic response requires 2 to 4 weeks2\text{ to }4\,\text{weeks} of continuous administration.


SSRIs Clinical Indications and Adverse Effects
  • Common Side Effects:

    • Gastrointestinal upset (nausea, vomiting, diarrhea)

    • Headache, insomnia, or somnolence

    • Lethargy and fatigue

    • Sexual dysfunction (decreased libido, anorgasmia, erectile dysfunction)

    • Weight gain

    • Significantly fewer anticholinergic effects compared to tricyclic antidepressants.

  • Herbal Interactions: St. John's Wort must be avoided due to severe risk of serotonin toxicity.

  • Antidepressant Discontinuation Syndrome:

    • Occurs following abrupt cessation of SSRI therapy.

    • Clinical Mnemonic (FINISH):

    • F: Flu-like symptoms (lethargy, myalgias)

    • I: Insomnia with vivid dreams or nightmares

    • N: Nausea (occasionally vomiting)

    • I: Imbalance (dizziness, vertigo, lightheadedness)

    • S: Sensory disturbances (paresthesias, "brain zaps")

    • H: Headaches

  • FDA Black Box Warning: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (<24 years<24\,\text{years}). Requires close clinical monitoring for worsening depression or emergence of suicidality.

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

  • Representative Agents: Venlafaxine (Effexor), Duloxetine (Cymbalta).

  • Mechanism of Action: Dual inhibition of presynaptic serotonin and norepinephrine reuptake transporters.

  • Side Effect Profile: Similar to SSRIs with low anticholinergic activity; can cause dose-dependent elevations in blood pressure.

Serotonin Syndrome

  • Etiology: Potentially fatal hyper-serotonergic state caused by excessive serotonergic stimulation. High risk occurs when combining SSRIs with MAOIs, lithium, meperidine, triptans, or cocaine, or following rapid dose titration.

  • Onset: Rapid onset, typically within 3 to 6 hours3\text{ to }6\,\text{hours} of drug administration or dosage change.


Serotonin Syndrome Clinical Presentation and Mnemonic
  • Clinical Mnemonic (SHIVERS):

    • S: Shivering

    • H: Hyperreflexia and myoclonus

    • I: Increased temperature (hyperthermia)

    • V: Vital sign instability (autonomic instability, tachycardia, labile BP)

    • E: Encephalopathy (mental status changes: confusion, agitation, lethargy, coma)

    • R: Restlessness and motor hyperactivity

    • S: Sweating (diaphoresis)

  • Differential Diagnosis: Unlike Anticholinergic Toxidrome (which presents with dry skin and absent bowel sounds), Serotonin Syndrome features diaphoresis, hyperactive bowel sounds, nausea, vomiting, and diarrhea ("hot and wet").

  • Nursing and Emergency Interventions:

    • Discontinue all serotonergic agents immediately.

    • Notify healthcare provider.

    • Expect order for Cyproheptadine (a 5-HT1A5\text{-HT}_{1\text{A}} and 5-HT2A5\text{-HT}_{2\text{A}} receptor antagonist).

    • Implement cooling blankets or tepid sponge baths.

    • Provide continuous vital sign monitoring, fluid management (I&O), and seizure precautions.

Tricyclic Antidepressants (TCAs)

  • Representative Agents: Amitriptyline (Elavil), Nortriptyline (Pamelor), Doxepin (Sinequan), Imipramine (Tofranil).

  • Mechanism of Action: Non-selectively inhibit reuptake of norepinephrine and serotonin. Also block muscarinic acetylcholine, histamine H1\text{H}_1, and alpha-1 adrenergic receptors.

  • Clinical Indications: Endogenous depression, reactive depression, and depression associated with alcohol or cocaine withdrawal.

  • Onset: Requires 2 to 4 weeks2\text{ to }4\,\text{weeks} for therapeutic efficacy. Do not stop abruptly.


Tricyclic Antidepressants Clinical Summary
  • Side Effect Profile:

    • Sedation (histamine H1\text{H}_1 blockade)

    • Orthostatic hypotension and reflex tachycardia (alpha-1 blockade)

    • Decreased sexual desire/ability

    • Weight gain

  • Anticholinergic Side Effects and Toxidrome:

    • "Blind as a bat": Mydriasis (dilated pupils), loss of accommodation, blurred vision.

    • "Hot as a desert": Hyperthermia due to suppression of sweating.

    • "Red as a beet": Flushed, vasodilation of cutaneous blood vessels.

    • "Dry as a bone": Dry mouth (xerostomia), urinary retention, constipation, absent bowel sounds.

    • "Mad as a hatter": Confusion, delirium, hallucinations, agitation, fine tremors, picking at invisible objects.

    • Cardiac Toxicity: Risk of lethal cardiac dysrhythmias (QRS prolongation) in overdose.


Anticholinergic Toxidrome Diagnostic Features

Other Antidepressant Classes

  • Serotonin-Norepinephrine Disinhibitors (SNDIs):

    • Enhance serotonin and norepinephrine release.

    • Used in combination with SSRIs to augment efficacy or counter serotonergic side effects (e.g., sexual dysfunction).

  • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs):

    • Example: Bupropion (Wellbutrin).

    • Mechanism: Inhibits dopamine and norepinephrine reuptake with no action on serotonin. Inhibits nicotinic acetylcholine receptors to aid smoking cessation.

    • Caution: Dose-dependent risk of seizures; contraindicated in eating disorders.

  • Serotonin Antagonist/Reuptake Inhibitors (SARIs):

    • Example: Trazodone (Desyrel).

    • Clinical Use: Second-line antidepressant, highly sedating, commonly prescribed off-label for insomnia.

    • Adverse Effect: Risk of priapism (painful, sustained erection requiring medical intervention).

  • Selective Norepinephrine Reuptake Inhibitors (NRIs):

    • Example: Atomoxetine (Strattera).

    • Indication: Treatment of ADHD in patients who cannot tolerate stimulants; lacks significant antidepressant efficacy.

Antianxiety and Sedative-Hypnotic Medications

Anxiolytic Classes and Mechanisms

  • Therapeutic Uses: Treatment of acute and chronic anxiety disorders, acute alcohol withdrawal symptoms, skeletal muscle spasms, convulsive disorders, and preoperative sedation.

  • Mechanism of Action: Depress subcortical CNS levels by potentiating GABA activity (increasing chloride ion channel influx), causing neuronal hyperpolarization resulting in sedation, hypnosis, or coma.


Benzodiazepine Mechanism of Action at the GABA-A Receptor
  • Benzodiazepines:

    • Anxiolytic Focus: Diazepam (Valium), Clonazepam (Klonopin), Alprazolam (Xanax), Lorazepam (Ativan).

    • Note: Lorazepam and Alprazolam provide therapeutic anxiolysis with less soporific (sleep-inducing) sedation at lower doses.

    • Insomnia Focus: Flurazepam (Dalmane), Triazolam (Halcion).

  • Non-Benzodiazepine Anxiolytics:

    • Buspirone (Buspar): Reduces anxiety without producing sedation, muscle relaxation, cognitive impairment, or euphoric effects. Low abuse potential; does not cause physical dependence.

Short-Acting Sedative-Hypnotics and Melatonin Agonists

  • Non-Benzodiazepine "Z-Hypnotics":

    • Agents: Zolpidem (Ambien), Zaleplon (Sonata), Eszopiclone (Lunesta).

    • Action: Selective binding to GABA receptor subunits to induce sedative/hypnotic effects without antianxiety, anticonvulsant, or muscle relaxant properties.

  • Melatonin-Receptor Agonist:

    • Ramelteon (Rozerem): Hypnotic agent that acts selectively on melatonin MT1MT_1 and MT2MT_2 receptors in the suprachiasmatic nucleus to regulate circadian sleep cycles.

Patient Safety and Nursing Considerations

  • High potential for physical and psychological dependence with long-term benzodiazepine use.

  • Common Side Effects: Central nervous system depression—drowsiness, confusion, ataxia, lethargy, orthostatic hypotension.

  • Severe Interactions: Concomitant use with alcohol, opioid analgesics, other CNS depressants, sedating antihistamines, cimetidine, TCAs, neuromuscular blockers, or disulfiram can lead to severe respiratory depression, coma, and death.

Mood Stabilizers

Lithium Carbonate

  • Representative Formulations: Lithobid, Lithonate, Lithotabs.

  • Mechanism of Action: Alters sodium ion transport in nerve and muscle cells; inhibits presynaptic release of norepinephrine and dopamine; alters intracellular second messenger systems (e.g., inositol phospholipid pathway).

  • Therapeutic Index: Narrow therapeutic window requiring routine serum blood concentration monitoring.

  • Blood Level Ranges:

    • Acute Mania Level: 1.0 to 1.5 mEq/L1.0\text{ to }1.5\,\text{mEq/L}

    • Maintenance Level: 0.6 to 1.2 mEq/L0.6\text{ to }1.2\,\text{mEq/L}

    • Toxic Level: >2.0 mEq/L> 2.0\,\text{mEq/L}

  • Long-Term Adverse Effects: Chronic lithium usage increases the risk of renal failure (nephrogenic diabetes insipidus) and thyroid disorders (hypothyroidism).

  • Common Side Effects: Drowsiness, dizziness, headache, dry mouth, polydipsia (thirst), GI distress (nausea/vomiting), fine hand tremor, hypotension, pulse dysrhythmias, polyuria, dehydration, weight gain.

  • Signs of Lithium Toxicity:

    • Initial/Early Toxicity: Blurred vision, ataxia, tinnitus, persistent nausea/vomiting, severe watery diarrhea.

    • Advanced Toxicity: Severe or coarse hand tremors, severe GI pain, unsteadiness/stumbling gait, slurred speech (dysarthria), muscle twitching/fasciculations, clumsiness, severe confusion, muscle weakness, seizures, coma.

  • Nursing Considerations: Ensure adequate dietary fluid (2 to 3 L/day2\text{ to }3\,\text{L/day}) and consistent sodium intake. Hyponatremia inhibits lithium excretion, leading to toxic accumulation.

Anticonvulsant Mood Stabilizers

  • Valproate / Valproic Acid (Depakote, Depakene):

    • First-line for bipolar patients unresponsive to lithium or experiencing rapid-cycling.

    • Inhibits metabolism of lamotrigine, increasing its serum concentrations.

    • Side Effects: Nausea, vomiting, drowsiness, dizziness, blood dyscrasias, prolonged bleeding time, hepatotoxicity, pancreatitis.

  • Lamotrigine (Lamictal):

    • Effective for bipolar depression maintenance.

    • Dermatological Warning: High risk for triggering a life-threatening, severe cutaneous reaction known as Stevens-Johnson Syndrome (SJS).

    • Patient Teaching: Instruct patient to report any skin rash immediately.


Stevens-Johnson Syndrome Clinical Manifestation with Mucosal Involvement
  • Carbamazepine (Tegretol):

    • Effective in rapid-cycling bipolar disorder and acute mania.

    • Adverse Effects: Rare but fatal blood dyscrasias (agranulocytosis, aplastic anemia).

  • Topiramate (Topamax): Off-label mood stabilizer; reduces efficacy of oral contraceptives; weight neutral or weight loss.

  • FDA Black Box Warning (December 2008): All antiepileptic/anticonvulsant drugs carry an increased risk of suicidal thoughts and behaviors.

  • Off-Label Mood Stabilizers: Oxcarbazepine (Trileptal), Gabapentin (Neurontin), Topiramate (Topamax).

  • Patient and Family Education:

    • Do not stop taking anticonvulsants abruptly.

    • Immediately report: skin rash, unusual bleeding, spontaneous bruising, sore throat, fever, malaise, dark urine, or yellowing of skin/eyes (jaundice).

    • Avoid alcohol and OTC drugs without physician approval.

Antipsychotic Medications

Overview and Clinical Goals

  • Indication: Alleviate psychotic symptoms (delusions, hallucinations, thought disorganization) associated with schizophrenia and bipolar disorder.

  • Cure vs. Symptom Management: Antipsychotics control symptoms but do not cure the underlying psychiatric condition. Medication non-adherence leads to rapid symptom relapse.

  • Categorization:

    • First-Generation Antipsychotics (FGA / Conventional / Typical).

    • Second-Generation Antipsychotics (SGA / Atypical).

Clinical Features of Schizophrenia


Comparison of Positive versus Negative Symptoms of Schizophrenia
  • Positive Symptoms (Excess or distortion of normal function - should not be present):

    • Visual hallucinations

    • Auditory hallucinations

    • Delusional thinking

    • Disorganized speech and behavior

    • Agitated, catatonic, or repetitive motor movements

  • Negative Symptoms (Deficit or loss of normal function - should be present):

    • Flat or blunted affect

    • Social isolation and withdrawal

    • Apathy

    • Anergia (lack of energy)

    • Anhedonia (inability to feel pleasure)

    • Alogia (reduced speech content)

First-Generation Antipsychotics (FGAs)

  • Mechanism of Action: Dopamine receptor antagonists (DRAs) that selectively block Dopamine type 2 (D2\text{D}_2) receptors in the brain, reducing dopaminergic transmission.

  • Therapeutic Spectrum: Target positive symptoms of schizophrenia effectively; ineffective for negative symptoms.

  • Subclasses by Potency:

    • High-Potency: Haloperidol (Haldol), Fluphenazine (Prolixin) — high risk of EPS, lower anticholinergic/sedative effects.

    • Moderate-Potency: Perphenazine (Trilafon).

    • Low-Potency: Chlorpromazine (Thorazine) — low risk of EPS, high sedating, hypotensive, and anticholinergic effects.

Extrapyramidal Side Effects (EPS) and Adverse Reactions


Extrapyramidal Side Effects Manifestations
  • Acute Dystonia:

    • Sudden, painful muscle spasms/stiffness of the face, neck, back, or tongue (back spasms cause trunk to arch forward).

    • Facial grimacing, involuntary upward eye movement (oculogyric crisis).

    • Laryngeal spasms (medical emergency threatening airway).

  • Akathisia:

    • Subjective intense motor restlessness.

    • Inability to sit still, pacing the floor, constant shifting of feet, rocking back and forth.

  • Pseudoparkinsonism:

    • Drug-induced parkinsonian symptoms.

    • Stooped posture, shuffling gait, muscle rigidity, bradykinesia, resting tremors, pill-rolling motion of the hand.

  • Tardive Dyskinesia (TD):

    • Involuntary, irreversible neurological movement disorder resulting from chronic D2\text{D}_2 blockade.

    • Protrusion and rolling of the tongue, sucking and lip-smacking, chewing movements, facial dyskinesia, choreoathetoid movements of the trunk and extremities.

  • Neuroleptic Malignant Syndrome (NMS):

    • Rare, life-threatening emergency occurring 2 to 10 days2\text{ to }10\,\text{days} after starting or escalating FGA therapy (or abrupt withdrawal of dopaminergic agonists in Parkinson's).


Neuroleptic Malignant Syndrome Features, Diagnostic Mnemonic, and Differential
  • Clinical Mnemonic (FEVER):

    • F: Fever (hyperthermia, temperature >103∘F>103^\circ\text{F}/39.4∘C39.4^\circ\text{C})

    • E: Encephalopathy / Altered Mental Status (AMS)

    • V: Vitals instable (autonomic instability: tachycardia, labile BP, tachypnea)

    • E: Elevated CPK (creatine phosphokinase due to severe rhabdomyolysis) and Leukocytosis

    • R: Rigidity ("lead-pipe" muscle rigidity)

  • Classic NMS Tetrad: Altered mental status, extreme hyperthermia, severe muscle rigidity, autonomic instability.

Receptor Blockade Side Effect Profiles


Systemic Adverse Effects Resulting from Antipsychotic Receptor Antagonism
  • Dopamine D2\text{D}_2 Receptor Blockade:

    • Antipsychotic effect (reduces positive symptoms).

    • Extrapyramidal side effects (EPS).

    • Hyperprolactinemia: Men (gynecomastia), Women (galactorrhea, amenorrhea).

  • Muscarinic Cholinergic Receptor Blockade:

    • Dry mouth, blurred vision, urinary retention/hesitancy, constipation, tachycardia.

  • Histamine H1\text{H}_1 Receptor Blockade:

    • Sedation, drowsiness, substantial weight gain, orthostasis.

  • Alpha-1 (α1\alpha_1) Adrenergic Blockade:

    • Peripheral vasodilation, orthostatic hypotension, dizziness, reflex tachycardia, ejaculatory failure.

  • Alpha-2 (α2\alpha_2) Adrenergic Blockade:

    • Sexual dysfunction, priapism.

  • Serotonin 5-HT25\text{-HT}_2 Receptor Blockade:

    • Antipsychotic effect, weight gain, hypotension, ejaculatory dysfunction.

  • GABA Modulation:

    • Lowers seizure threshold.

Second-Generation (Atypical) Antipsychotics (SGAs)

  • Mechanism of Action: Dual serotonin-dopamine antagonists (block 5-HT2A5\text{-HT}_{2\text{A}} and D2\text{D}_2 receptors).

  • Therapeutic Advantages:

    • Effectively target both positive and negative symptoms of schizophrenia.

    • Significantly lower risk of extrapyramidal side effects (EPS) and tardive dyskinesia.

    • Help treat comorbid anxiety and depressive symptoms; reduce suicidal behaviors.

    • Improve overall functional quality of life.

  • Representative SGA Agents:

    • Clozapine (Clozaril) — requires regular blood monitoring for agranulocytosis risk.

    • Olanzapine (Zyprexa)

    • Risperidone (Risperdal)

    • Quetiapine (Seroquel)

    • Ziprasidone (Geodon)

    • Aripiprazole (Abilify) — dopamine system stabilizer / partial agonist.

    • Iloperidone (Fanapt)

    • Lurasidone HCl (Latuda)

    • Cariprazine (Vraylar)

  • Major Metabolic Risk (Metabolic Syndrome):

    • Substantial weight gain

    • Hyperglycemia / New-onset type 2 diabetes mellitus

    • Dyslipidemia (increased serum triglycerides)

    • Insulin resistance

Diagnostic Comparison of Key Syndromes

Differential Diagnosis Matrix

  • Serotonin Syndrome:

    • Primary Cause: Serotonergic agents (SSRIs, SNRIs, MAOIs, Triptans).

    • Onset: Rapid (3 to 6 hours3\text{ to }6\,\text{hours}).

    • Neuromuscular Findings: Hyperreflexia, myoclonus, shivering, tremor.

    • Autonomic/Skin Signs: Diaphoresis ("wet"), hyperactive bowel sounds, diarrhea, nausea.

    • Treatment: Discontinue drug, Cyproheptadine, cooling measures.

  • Neuroleptic Malignant Syndrome (NMS):

    • Primary Cause: Antipsychotic agents (D2\text{D}_2 blockers) or dopaminergic withdrawal.

    • Onset: Gradual (2 to 10 days2\text{ to }10\,\text{days}).

    • Neuromuscular Findings: Severe "lead-pipe" rigidity, bradykinesia, tremors.

    • Autonomic/Skin Signs: Diaphoresis, extreme fever, labile blood pressure, elevated CPK, leukocytosis.

    • Treatment: Discontinue drug, Dantrolene or Bromocriptine, intensive cooling.

  • Anticholinergic Toxicity:

    • Primary Cause: TCAs, Low-potency FGAs, Antihistamines, Antiparkinsonian drugs.

    • Neuromuscular Findings: Delirium, ataxia, shaking, grabbing invisible objects.

    • Autonomic/Skin Signs: Flushed skin ("red"), hyperthermia, dry skin/mouth ("dry as a bone"), urinary retention, absent bowel sounds.

    • Treatment: Discontinue drug, Physostigmine (if indicated), supportive care.